FDA authorizes a robot that draws blood without a phlebotomist's hands on the needle

The FDA announced on 19 August that it has authorized the Aletta, described as the first standalone robotic device that can draw blood from a patient's arm without an operator's hands directly performing the procedure [s1]. The device is authorized for use in adults in outpatient settings, under the oversight of a supervisor trained in phlebotomy [s1].

What the device actually does

A trained phlebotomist initiates each session, and the patient or supervisor presses a button to begin [s1]. From there, the Aletta uses near-infrared light and Doppler ultrasound to locate a suitable vein and distinguish it from nearby arteries; if it can't find an appropriate vein, it won't attempt the draw at all [s1]. Once it identifies a vein, the device proceeds through the remaining steps on its own — applying a tourniquet, preparing the skin, inserting and later disposing of the needle, switching collection tubes, and applying a bandage [s1]. The supervising phlebotomist's job shifts from performing the draw to confirming the tubes fill in the correct order and checking that each is adequately full afterward [s1]. FDA says one supervisor can now oversee up to three Aletta devices running at the same time [s1] — the number FDA and the agency's device center director, Dr. Michelle Tarver, frame as directly relevant to what she called a "growing shortage of trained phlebotomists" in the US [s1].

Why the FDA is framing this around a staffing shortage

FDA's announcement leads not with the robotics but with a workforce problem: "Blood draws are one of the most commonly performed medical procedures in the United States, yet patients may face delays due to a growing shortage of trained phlebotomists," Tarver said in the agency's release [s1]. FDA characterized the authorization as advancing three of its stated public health priorities — innovation and global leadership, increasing access to affordable medicines and medical products, and preventing chronic disease and promoting wellness — by bringing what it called "a transformative technology to patients who increasingly face delays in accessing a critical diagnostic service" [s1]. That framing matters for how the device is likely to be deployed first: not as a novelty in a hospital already staffed with phlebotomists, but in outpatient clinics and labs where a shortage is already causing wait times, letting a single supervisor's time stretch across more patients per shift.

Built-in stops, not just built-in automation

The safety design leans on the device refusing to proceed rather than just executing carefully. Beyond declining the draw when it can't confirm a vein, the Aletta continuously applies disinfectant to the skin during its ultrasound scan and is cleaned by a trained professional between patients [s1]. If a patient moves too much mid-procedure, the needle automatically detaches and the draw stops; other onboard sensors can pause the process and alert the supervisor if they detect other unsafe conditions [s1].

The evidence FDA reviewed

FDA says its authorization rests on clinical data showing the Aletta achieves successful blood-draw rates comparable to or better than trained human phlebotomists when it proceeds with a stick [s1]. That testing spanned a broad range of patients, including people with varying health statuses, those who self-reported difficult vein access, and those with varying skin tones [s1] — a detail the agency called out specifically, since vein-finding technology has historically underperformed on some of exactly those groups. FDA characterized device-related adverse events in testing as uncommon and mild, without providing a specific rate [s1].

The regulatory mechanism: a new category, not just one product

FDA granted the authorization to the manufacturer, Vitestro, through the De Novo pathway — the route used for novel low- to moderate-risk device types that don't have an existing, comparable product already on the market [s1]. Alongside the authorization, FDA is establishing special controls specific to this new device category: defined requirements for labeling, performance testing and clinical testing that any company bringing a similar autonomous phlebotomy device to the US market will now have to meet [s1]. In practice, that means the Aletta's clearance sets the baseline rules for competitors, not just a one-off approval.

What it doesn't do yet

The authorization is limited to adults in outpatient settings, and a trained phlebotomy supervisor still has to be present and involved at each stage — this is not an unsupervised device, and FDA's framing treats it as a way to extend one supervisor's reach rather than eliminate the role [s1]. FDA's release does not address pediatric use, inpatient or emergency settings, or a timeline for wider commercial rollout.